...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on drug safety >Safety profile and bleeding risk of ticagrelor compared with clopidogrel
【24h】

Safety profile and bleeding risk of ticagrelor compared with clopidogrel

机译：替格瑞洛与氯吡格雷相比的安全性和出血风险

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Ticagrelor is a novel, non-thienopyridine ADP inhibitor that reversibly blocks the P2Y12 receptor, preventing platelet activation and aggregation. It is the first ADP inhibitor to show a mortality benefit in patients with acute coronary syndromes (ACS). Its major safety concern, as with the other ADP blockers, is bleeding. Other common adverse effects of ticagrelor such as dyspnea and ventricular pauses appear to be mild and self-limited. Areas covered: The pharmacological properties of ticagrelor compared with clopidogrel are explored in this article. In addition, the relevant clinical trials in which ticagrelor was investigated are described, with an emphasis on efficacy and safety end points. Expert opinion: Although some patients suffer from dyspnea when administered with ticagrelor, there is no evidence of any untoward effects on the cardiovascular or pulmonary systems. Given that the majority of these episodes are mild to moderate and self-limiting, patients should be encouraged to continue the medication, as symptoms may resolve. Furthermore, patients with underlying heart failure or lung disease do not appear to be at an increased risk of developing ticagrelor-induced dyspnea. Its overall mortality benefit among patients with ACS, along with its ability to inhibit platelet aggregation more rapidly and consistently, makes it the preferred agent over clopidogrel.
机译：简介：替卡格雷（Ticagrelor）是一种新型的非噻吩并吡啶ADP抑制剂，可逆性阻断P2Y12受体，防止血小板活化和聚集。它是第一种在急性冠脉综合征（ACS）患者中显示出死亡获益的ADP抑制剂。与其他ADP阻滞剂一样，它的主要安全隐患是出血。替格瑞洛的其他常见不良反应，例如呼吸困难和心室停顿，似乎是轻度的，并且是自我限制的。涵盖领域：本文探讨了替卡格雷与氯吡格雷相比的药理特性。此外，还介绍了有关替卡格雷治疗的相关临床试验，重点是疗效和安全性终点。专家意见：尽管有些患者在接受替卡格雷治疗时出现呼吸困难，但没有证据表明对心血管或肺系统有不良影响。鉴于这些发作中的大多数是轻度至中度和自限性，应鼓励患者继续用药，因为症状可能会缓解。此外，潜在的心力衰竭或肺部疾病患者似乎没有发生替卡格雷洛引起的呼吸困难的风险增加。它在ACS患者中的整体死亡率获益，以及更迅速，持续抑制血小板聚集的能力，使其成为优于氯吡格雷的首选药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号